Conference Call

Mid-Week Update 04-21-10

Earnings season is hitting its stride. Over 100 of S&P 500 companies have already reported first quarter results, and it appears we’re on track for a relatively positive season. In fact, of those who have released, over 80 percent have surprised on the upside, while less than 10 percent have come in below expectations.
 
The poster child for positive earnings surprises, Apple (AAPL), reported another blockbuster quarter (its fiscal 2nd quarter) after the market closed yesterday. Our Growth Portfolio member reported revenues of $13.5 billion, up 49 percent, easily outpacing analysts’ expectations of $12 billion. Earning per share beat expectations by even more at $3.33 vs. consensus estimates of $2.46, as the company reported impressive gross margins of 41.7 percent, almost 3 percentage points better than company’s earlier guidance. Earnings were helped by a strong mix of product sales, including higher-margined Mac computers, whose shipments grew by 33 percent vs. the year earlier period. The company’s largest revenue contribution came from the iPhone unit, with sales of $5.3 billion. The company sold 8.75 million units during the quarter, up an astounding 131 percent from a year earlier, and more than 3 times the 41 percent growth seen in the smartphone market as a whole.
Read more...

Mid-Week Update 11-11-09

Earnings season marches on, with over 90 percent of S&P 500 companies having reported. Over 80 percent of those reported have had positive earnings surprises, but we can attribute much of that to the same cost-cutting measures we’ve seen over the last few quarters. What has been somewhat surprising is that almost half those reporting have also beat estimates with their top-line or revenue numbers, while only 30 percent have fallen short of estimates.  Read more...

Market Update 05-04-05

 Visitors attend Baghdad...

Image by Getty Images via Daylife

Weekly Update 

Amylin received the approval they were seeking for Byetta with a favorable label. In addition, the FDA informed the company that they could seek the use of the drug as a stand-alone treatment, which is a bonus they weren't expecting. Regardless of whether it's marketed as a stand-alone therapy or in conjunction with other therapies, as a first-in-class drug Byetta has the potential to be a blockbuster, generating $1 billion to $2 billion in annual sales.Read more...

Market Update 05-04-05

 business leaders

Image by squareintheteeth via Flickr

May 4, 2005 

Update


Amylin Pharmaceutical's conference call this afternoon went a long way to clarifying investors' misperceptions surrounding Byetta and the FDA's labeling of the drug. The company also reinforced the market potential of the drug. And the market potential for Byetta is big.Read more...